PWPaweł Wiśniewski

Paweł Wiśniewski

*This is an algorithmically generated author record based on publicly available information.

Paweł Wiśniewski has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Double-blind, placebo-controlled randomised clinical trial on flexible doses of escitalopram and naltrexone in the treatment of men with compulsive sexual behaviour disorder: study protocol presentation

    by Michał Lew-Starowicz, Małgorzata Draps, Kacper Wilk, Pawel Wisniewski, Mateusz Gola

    Background Recent research has led to a better understanding of biological and psychosocial correlates of compulsive sexual behaviour disorder (CSBD). Psychotherapy is considered a first-line treatment strategy, while evidence on the use of pharmacotherapy is still scarce. This study aimed to provide new data on the efficacy of a selective serotonin reuptake inhibitor and an opioid receptor antagonist used as monotherapy or in combination in CSBD. Methods and analysis 410 adult men seeking treatment due to perceived loss of control over sexual behaviour and its negative consequences, meeting the ICD-11 diagnostic guideline of CSBD and scoring ≥50 on the Compulsive Sexual Behavior Disorder Scale, used for assessment of CSBD according to ICD-11 guidelines (CSBD-19) questionnaire, will be randomised to 24-week, double-blind treatment with either escitalopram 10–20 mg, naltrexone 25–50 mg, combined treatment or placebo (fixed- and flexible-dosing for the first and subsequent 12 weeks, respectively) with a 12-month follow-up after completing the medication. Men with relevant psychiatric or neurological comorbidity or cognitive impairment, with current psychoactive substance dependence or compulsive gambling, already using psychotropic medications, with positive drug test or significant blood lab test abnormality, or any medical or concomitant treatment-related contraindications for use of any of the investigated medications will be excluded from participation in this clinical trial. Patients will be assessed using structured clinical interviews, validated questionnaires, ecological momentary assessment and functional electroencephalography. Pharmacovigilance and lab tests will be provided throughout the active treatment phase to monitor its safety and tolerability. Main outcome measure will include changes in the severity of symptoms of compulsive sexual behaviours operationalised using CSBD-19 and Brief Pornography Screen (BPS) questionnaires as well as diary assessments. A mixed multivariate analysis of variance (MANOVA) model will be applied with three measurements (before therapy initiation, after 12—primary endpoint and 23 weeks of treatment—secondary endpoint) in the four treatment arms. Regression models will be used in the search of predictors of clinical outcomes and correlation analyses to measure the relationship between psychometric outcomes, diary variables and neuronal biomarkers. Ethics and dissemination Ethical approval was granted as part of the Clinical Trials Information System (CTIS) Part II assessment in Poland on 17 February 2025. The trial was authorised in Poland on 24 February 2025 (EU CT approval reference: 2024-514490-22-01). The results of the study will be presented during conferences and published in peer-reviewed journals. Trial registration number EUCT: 2024-514490-22-01.

  • Alcohol use and interoception – A narrative review

    by Paweł Wiśniewski, Pierre Maurage, Andrzej Jakubczyk, Elisa M. Trucco, Hubert Suszek, Maciej Kopera


  • Open Access

    Pain Sensitivity, Negative Affect, and Alcohol Use Disorder Status: A Moderated Mediation Study of Emotion Dysregulation

    by Maciej Kopera, Elisa M. Trucco, Hubert Suszek, Paweł Kobyliński, Paweł Wiśniewski, Marcin Wojnar, Andrzej Jakubczyk

    Previous work suggests that the association between pain and emotional processes among individuals with alcohol use disorder (AUD) may differ from healthy controls. This study investigates whether pain sensitivity mediates the association between negative affect and emotional dysregulation and whether this association differs across AUD status using moderated mediation. The sample included 165 individuals diagnosed with AUD and 110 healthy controls. Of interest was pain sensitivity, as assessed with the Pain Sensitivity Questionnaire, negative affect, as assessed with the Beck Depression Inventory, and emotional dysregulation, as assessed with the Difficulties in Emotional regulation Scale. Age, biological sex, and current pain severity were included as covariates. The results support a moderated partial mediation model that explained 44% of the variance in emotional dysregulation. The findings indicate that negative affect is related to higher pain sensitivity across groups. Moreover, pain sensitivity partially mediated the association between negative affect and emotional dysregulation, but in opposite directions depending on AUD status. Among healthy controls, greater pain sensitivity was related to better emotional regulation, while greater pain sensitivity led to greater emotional dysregulation among individuals with AUD. The potential parallels in the underlying neurobiological mechanisms of emotionality, pain, and AUD suggest that interventions targeting pain may improve adaptive affect regulation skills, which in turn could reduce negative affect and its effect on pain sensitivity among individuals with AUD.